12
Participants
Start Date
June 12, 2024
Primary Completion Date
November 30, 2026
Study Completion Date
December 31, 2031
AAV9-hSyn1-miGRIK2
AMT-260 is an AAV9 gene therapy product that locally delivers miRNA silencing technology to target the GRIK2 gene and suppress aberrantly expressed GluK2 containing kainate receptors. Intervention will be a one-time intracerebral administration of AMT-260.
NOT_YET_RECRUITING
Allegheny Health Network, Pittsburgh
RECRUITING
Hospital of the University of Pennsylvania, Philadelphia
RECRUITING
Midatlantic Epilepsy and Sleep Center, Bethesda
RECRUITING
Johns Hopkins School of Medicine, Baltimore
RECRUITING
Mayo Clinic Florida, Jacksonville
RECRUITING
Ohio State University, Columbus
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Corewell Health, Grand Rapids
NOT_YET_RECRUITING
Medical College of Wisconsin, Milwaukee
NOT_YET_RECRUITING
Kansas University Medical Center, Kansas City
RECRUITING
Baylor Scott & White Medical Center, Austin
RECRUITING
Mayo Clinic Arizona, Phoenix
RECRUITING
Stanford University, Palo Alto
RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dartmouth Hitchcock Medical Center, Lebanon
RECRUITING
Northeast Regional Epilepsy Group, Hackensack
RECRUITING
Robert Wood Johnson Hospital, New Brunswick
UniQure Biopharma B.V.
INDUSTRY